Androgen receptor PROTACS
Grant
US12577231B2
Kind: B2
Mar 17, 2026
Assignee
GlaxoSmithKline Intellectual Property Development Limited
Inventors
Christopher Patrick Tinworth, Laura Trulli
Abstract
Certain Androgen receptor PROTAC (PROteolysis TArgeting Chimera) compounds contain a series of 2,4-dioxotetrahydropyrimidinyl derivatives that bind cereblon. The PROTAC compounds may be viewed as being comprised of an androgen receptor binding moieties, a linker and a cereblon binding moiety or degron. Medical uses of these PROTAC compounds are also disclosed.
CPC Classifications
C07D 401/14
C07D 405/14
C07D 471/04
C07D 487/04
A61P 35/00
Filing Date
2025-06-30
Application No.
19254759
Claims
28